Zika vaccine candidate enters human safety testing
⭐️ VACCINE ⭐️
Completed
This early-stage trial tested an inactivated Zika virus vaccine (VLA1601) in 150 healthy adults aged 18-49. Participants received two doses, and researchers monitored side effects and immune responses. The goal was to find the safest and most effective dose, including combination…
Phase: PHASE1 • Sponsor: Valneva Austria GmbH • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 11:00 UTC